Navigation Links
Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
Date:3/16/2009

SP-specific BiTE antibody at very low effector to target ratios: A new approach to treat metastatic melanoma. AACR Annual Meeting 2009, abstract no. 3248; to be presented in session 'Immunology 5' on April 21, 2009, 8:00 AM in Hall B-F, poster section 12.
  • Aigner, M. et al. (2009). Effective in vitro lysis of human melanoma cell lines by T lymphocytes redirected with a MCSP/CD3-bispecific single-chain antibody construct is independent of the expression of tumor-associated antigens gp100, MART-1, tyrosinase and NY-ESO1. AACR Annual Meeting 2009, abstract no. 4152; to be presented in session 'Immunology 6' on April 21, 2009, 1:00 PM in Hall B-F, poster section 11.
  • Abstracts can be accessed at http://www.aacr.org.

    About Micromet

    Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, MD and Munich, Germany. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all
    '/>"/>

    SOURCE Micromet, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
    2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
    3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
    4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
    5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
    6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
    7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
    8. Micromet to Present at Two Upcoming Investor Conferences
    9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
    10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
    11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
    (Date:2/27/2015)... ADELAIDE, Australia , Feb. 27, 2015 ... data from the DisrupTOR-1 trial of BNC105 in patients ... Symposium in Orlando, Florida . The ... of the City of Hope Comprehensive Cancer Center ... presentation. The new data identifies Ferritin ...
    (Date:2/27/2015)... Brighton, Illinois (PRWEB) February 27, 2015 ... Matt Sims, General Manager of State Line Farms, received ... Award recognizes a producer, under the age of 35, ... , "It is an honor to win the Tomorrow's ... to discovering who won the Top Producer Award and ...
    (Date:2/27/2015)... -- Steep Hill, the industry leader in cannabis testing and ... a full service medical cannabis quality assurance laboratory in ... scientific tools and methodology to the state, for regulatory ... the only laboratory licensed by the New Mexico Department ... order to meet the recently adopted regulatory requirements pertaining ...
    Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2
    ... March 31 DOR BioPharma, Inc. (OTC Bulletin Board: ... today announced its financial results for 2008. DOR,s revenues ... million in 2007. The increase was due primarily ... the resulting achievement of certain research and development milestones ...
    ... IDM Pharma, Inc. (Nasdaq: IDMI ) today ... ended December 31, 2008. Financial information presented represents the ... Pharma S.A.Total revenues in the quarter ended December 31, 2008 ... $0.07 per share for the quarter. Total revenues for ...
    ... leader of cell line manufacturing, Selexis is now ... recombinant protein drugs with added characterization servicesGENEVA, March ... offering technologies and services for the rapid development ... an expanded offering focusing on the biosimilar market ...
    Cached Biology Technology:DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 5IDM Pharma Reports 2008 Financial Results 2IDM Pharma Reports 2008 Financial Results 3IDM Pharma Reports 2008 Financial Results 4IDM Pharma Reports 2008 Financial Results 5IDM Pharma Reports 2008 Financial Results 6IDM Pharma Reports 2008 Financial Results 7IDM Pharma Reports 2008 Financial Results 8Selexis Launches Biosimilar Cell Line Development Program 2
    (Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
    (Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
    (Date:1/22/2015)... NEW YORK , Jan. 21, 2015  Analyst Report Issued ... Credit Card Brands report showed that planet-wide, transactions at merchants ... 2011, while the total number of credit, debit, and prepaid ... the U.S. were victims of fraudulent card usage in 2012, ...
    Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
    ... Want to slow the signs of aging and live ... calories could be a promising strategy. Calorie restriction ... rats and mice. While scientists do not know how calorie ... is that it slows aging by decreasing a thyroid hormone, ...
    ... a bold commitment from Germany, leaders of the world,s ... Summit in Japan to take immediate and substantive action ... pledge of 500 million Euros over four years to ... forest protection, starts to address a major source of ...
    ... COLLEGE STATION, July 2, 2008 -- Two Texas A&M ... help scientists more accurately study complex units of clustered ... scientists to analyze many bacterial genomes at once, is ... experimentally validated data instead of from statistical predictions, they ...
    Cached Biology News:Looking for the Founatain of Youth? Cut your calories, research suggests 2G8 summit: Opportunity for immediate action on climate change 2G8 summit: Opportunity for immediate action on climate change 3Texas A&M researchers develop tool to study complex clusters of genes 2Texas A&M researchers develop tool to study complex clusters of genes 3
    ... have moderate chemiluminescence efficiencies and the chemistry ... have the added benefit that they require ... the background signal. This benefit has been ... immunoassay applications. These compounds can also be ...
    Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
    ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
    ... version of Freezerworks Unlimited includes 2 clients and ... facilitates the sharing of freezers by multiple groups ... Network Client/Server version ... in monitor with 256 colors; OS 8.6 & ...
    Biology Products: